Luspatercept for anemia after AML treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of acute myeloid leukemia (AML) that is not related to a previous blood cancer or treatment.
- You are between 18 and 60 years old.
- Your AML is classified as low risk according to the ELN 2022 guidelines.
- You have completed 1 to 3 cycles of high-dose consolidation chemotherapy.
- Your hemoglobin level (red blood cell count) is between 60 and 90 grams per liter (mild to moderate anemia).
- You are able to care for yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests a drug called luspatercept to see if it can help your body make blood cells faster after a stem cell transplant. It is for people with blood cancers and moderate to severe bone marrow scarring (myelofibrosis).
This study tests two medicines, luspatercept and epoetin, to see which one helps the body make more red blood cells after a stem cell transplant. If you have low red blood cell counts after your transplant, this trial may help improve your energy and reduce the need for transfusions.
This trial tests whether a medication called luspatercept can help raise red blood cells faster after a stem cell transplant for blood cancer. It aims to reduce severe anemia and improve recovery.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
Hear when a new Chemotherapy-inducing Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.